Kenneth Widder

SEngine Precision Medicine has appointed Siddhartha Mukherjee to its advisory Board. Mukherjee is the Pulitzer Prize-winning author of the "The Emperor of All Maladies: A Biography of Cancer." Mukherjee is also an assistant professor of medicine and leading cancer researcher at Columbia University.

Illumina has named Susan Siegel to its board of directors. Siegel is chief innovation officer at General Electric and CEO of GE Ventures, which invests in startups and commercializes GE's intellectual property. Prior to joining GE, she was a general partner at Mohr Davidow Ventures, where she led investments in personalized medicine, digital health, and life sciences. Siegel was a founding representative member of the National Institutes of Health's National Center for Advancing Translational Sciences and also served on the Precision Medicine Initiative Working Group of the Advisory Committee to the NIH Director.

Jonathan Symonds has been appointed as chair of Genomics England, replacing Sir John Chisholm, who stepped down this week. Symonds had been a senior non-executive director of the company since 2014.

In addition, John Mattick stepped down as CEO of Genomics England. He is temporarily replaced by Mark Caulfield, the company's chief scientist, who will serve as interim chief executive while a search for a permanent new CEO is ongoing.

Soren Germer has been promoted to senior VP of genome technologies of the New York Genome Center. He previously served as the center's senior scientific director of sequencing operations, and before that, sequencing program manager. In his new role, Germer will lead the activities of the NYGC's sequencing and analysis teams.

Also, Michael Zody has been promoted to scientific director of computational biology of the NYGC, a new role. Zody will continue to provide scientific leadership to the computational biology team as well as lead new grants, foster partnerships, and serve as strategic scientific advisor.

In addition, Ana Bastiani-Posner has joined the NYGC as senior VP of finance and administration. Previously, she held executive finance roles at Allergan, Novartis Pharmaceuticals, and Schering-Plough.

Metabolon has appointed Michael Rasche as its president of international business. Rasche will lead the firm's international business activities with a focus on customer and team expansion. Prior to Metabolon, Rasche acted as chief commercial officer at Definiens. Before Definiens, Rasche served as corporate VP of global commercial operations at Ayoxxa. He has also held leadership positions at Dako (now Agilent), Roche, and Bayer Diagnostics in Europe, as well as North and South America.

Deanna Church has joined gene editing technology company Inscripta as senior director of mammalian applications. Previously, she was senior director of applications at 10x Genomics, and before that, senior director of genomics and content at Personalis. Prior to that, she was a staff scientist at the National Center for Biotechnology Information. Church holds a PhD in genomics, genetics, and molecular biology from the University of California, Irvine, and a BA in liberal arts from the University of Virginia.